News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Aakash Desai: Lorlatinib vs. Crizotinib in 1L ALK+ lung cancer
Aakash Desai/LinkedIn
Mar 3, 2025, 13:06

Aakash Desai: Lorlatinib vs. Crizotinib in 1L ALK+ lung cancer

Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn about a paper by Yi-Long Wu et al. published in Journal of Thoracic Oncology:

“CROWN 5-year update: Asian subset

Lorlatinib vs. Crizotinib in 1L ALK lung cancer.

  • PFS HR 0.22 (NR vs. 9.2m)
  • 5-year PFS: 63% vs. 7%
  • iCRR: 69% vs. 6%

Consistent with overall study results. Strong PFS and intracranial efficacy remains key.”

“First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study”

Authors: Yi-Long Wu, Hye Ryun Kim, Ross Soo, Chew Hooi Wong, Tony Mok et al.

Aakash Desai: Lorlatinib vs. Crizotinib in 1L ALK+ lung cancer

More posts featuring Aakash Desai.

Aakash Desai ALK-positive NSCLC cancer Chew Hooi Wong Hye Ryun Kim NSCLC OncoDaily Oncology Ross Soo Tony Mok Yi-Long Wu
Special Coverage
Science
Mar 3, 2025, 13:06
Aakash Desai: Lorlatinib vs. Crizotinib in 1L ALK+ lung cancer
Blog
Mar 3, 2025, 13:03
Rita Sakr: Honored to be part of the 1st Saudi iBreast Book Oncoplastic Course and Cadaveric Workshop
Blog
Mar 3, 2025, 13:02
Rochelle G Prosser: Ever wonder what “Cancer Travel Tourism” is?
Blog
Mar 3, 2025, 13:00
Korede Akindele: Policy discussions shape meaningful change and drive impactful solutions
Blog
Mar 3, 2025, 13:00
WCLC 2025 Registration is now open - IASLC
Blog
Mar 3, 2025, 12:59
Al-Ola A Abdallah: Chemotherapy-Induced Peripheral Neuropathy Hematological Patients
Science
Mar 3, 2025, 12:52
5 papers about Lung Cancer suggested by Stephen Liu
Blog
Mar 3, 2025, 12:50
Fun walk/run to raise money for the MASCC Foundation
Blog
Mar 3, 2025, 12:48
Wafaa Rashed: An exclusive webinar exploring the latest Open Targets Platform update
Blog
Mar 3, 2025, 12:47
Peter Pisters: MD Anderson Cancer Center's Annual Report
Science
Mar 3, 2025, 12:45
Real-World Implications of the SOUND Trial by Andreas Giannakou et al.
Blog
Mar 3, 2025, 12:41
Jaime Grund: St. Elizabeth Healthcare showed up strong at the UK Precision Medicine Conference